Cross reactivity carboplatin cisplatin

Author: vxvc

August undefined, 2024

WebHypersensitivity reactions(HSRs) are a subset of IRs that occur at doses normally tolerated by patients and are not consistent with a known toxicity of the drug.2HSRs can be divided into subtypes as defined by Gell and Coombs, depending on the mechanism of reaction. WebJul 1, 2024 · This study demonstrates that cross-reactivity between carboplatin and oxaliplatin is very frequent, whereas cross-reactivity between cisplatin and the other …

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts

WebCarboplatin has established an important role in many different cancers. As its use increased, the documented cases of hypersensitivity also picked up. Although the … induction healing of porous asphalt concrete

Hypersensitivity and cross-reactivity to cisplatin and …

WebCarboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. Carboplatin sIgE is very specific but … WebCarboplatin and cisplatin have been shown to be effective chemotherapeutics and can be used to treat many solid tumors. Both carboplatin and cisplatin are platinum … WebThere seems to be no general cross-reactivity to cisplatin. Cancer 1994; 73:2218-22. Key words: carboplatin, chemotherapy, drug allergy, in- tracutaneous testing. All cytostatic drugs are able to induce allergic reactions. There are several reported instances of hypersensitivity reactions, primarily of the anaphylactic type (type I) but logan heart service

Low Cross-Reactivity Between Cisplatin and Other …

Response to Pembrolizumab After Dose-Reduced Cisplatin Plus

WebOct 27, 2016 · HSR are a common adverse event in patients rechallenged with carboplatin for ROC • Carboplatin-PLD is associated with a lower risk of developing HSR compared to other doublets • Several strategies have been developed to continue platinum-based therapy in these patients. • WebThe platinum 1,3-d (GXG) intrastrand cross-link is one of the adducts formed in the reaction of the antitumor drug cisplatin with DNA, and in fact the major adduct found in cells treated with the cisplatin analogue carboplatin. induction healthcare annual reportWebOct 14, 2024 · Cisplatin is a chemotherapy drug useful in treating testicular, ovarian, bladder, head and neck, lung, and cervical cancer. This compound is the prototype … induction healthcare rns

"WebPlatinum compounds, such as carboplatin and cisplatin, are commonly used for the treatment of endometrial, ovarian and testicular cancer. Conflicting studies have been reported with regards to the sensitivity of MMR deficient tumors cells to platinum treatment. " - Cross reactivity carboplatin cisplatin

Cross reactivity carboplatin cisplatin

Hypersensitivity Reactions to Carboplatin

WebJan 19, 2024 · Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated … Webcisplatin, and its toxicity profile is more favorable. Here we report on a 50-year-old woman with a history of cervix cancer who developed a severe hypersensitivity reaction (HSR) …

Did you know?

WebThe kinetics of the aquation reactions of cisplatin and carboplatin and their subsequent reactions with DNA, both in vitro and in vivo, have been measured. The results have … WebCisplatin and carboplatin may play an important role in the antitumor immune response, which could impact the outcome of subsequent pembrolizumab treatment. Given that the rate of response to pembrolizumab after dose-reduced GC chemotherapy was relatively low, this regimen is not recommended for cis …

WebHypersensitivity and cross-reactivity to cisplatin and analogues. We report on a 49-year-old woman with relapsing ovarian cancer who developed a hypersensitivity reaction (HSR) to … WebJul 1, 2024 · In contrast, cross-reactivity to CI was 0% (0 of 51) (95% CI: 0% to 7%) in OX-allergic patients and 7% (3 of 43) (95% CI: 2% to 17%) in CA-allergic patients. All these …

WebOct 5, 2014 · Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some studies show that cisplatin and carboplatin cause different morphological changes in MCF-7 cell lines while exerting their cytotoxic behavior (Natarajan, Malathi et al., 1999). The diminished reactivity limits protein-carboplatin complexes, which are excreted. WebA 49-year-old woman with relapsing ovarian cancer who developed a hypersensitivity reaction (HSR) to carboplatin and, subsequently, to cisplatin may prevent a small population of young patients from receiving effective therapy with cis platin or its analogues. We report on a 49-year-old woman with relapsing ovarian cancer who developed a …

WebThere appears to be cross-reactivity among the platinum complexes in that patients reactive to cisplatin have a much higher incidence of hypersensitivity to carboplatin than do previously nontreated patients. The severity of reactions ranges from mild pruritis and erythema to immediate life-threatening generalized anaphylaxis.

WebJul 1, 2003 · We believe there was a hypersensitivity and cross-reactivity to both carboplatin and cisplatin in this case, although some studies have reported safely administration of cisplatin in... induction healthcare ceoWebAug 2, 2024 · Carboplatin and cisplatin are commonly used for ovarian, lung, and head and neck cancers (Table 1) . Carboplatin-based regimens are frequently recommended … induction hbrWebFeb 1, 2024 · Cross-reactivity to CA in OX-allergic patients was 45% (23 of 51) (95% confidence interval [CI]: 36% to 66%) and cross-reactivity to OX in CA-allergic patients … induction healthcare attend anywhere